Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16088349 | 0.85 | PARP1 (0.39) | PARP1MCL1P2RX7KDM4EALDH1A1 | |
| SCHEMBL15298049 | 0.75 | PARP1 (0.43) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30104836 | 0.73 | PARP1 (0.38) | PARP1 | |
| SCHEMBL4549832 | 0.70 | CDK4 (0.50) | PARP1P2RX7ALDH1A1 | |
| SCHEMBL18638028 | 0.69 | PDCD1 (0.32) | P2RX7 | |
| SCHEMBL25950341 | 0.63 | PARP1 (0.43) | PARP1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23016499 | 0.62 | RPS6KA3 (0.48) | — | |
| SCHEMBL16151297 | 0.62 | PARP1 (0.43) | PARP1MCL1 | |
| SCHEMBL16091686 | 0.62 | CDK4 (0.48) | PARP1 | |
| SCHEMBL4549882 | 0.62 | CDK4 (0.34) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275067-A1 | Transient Protection of Normal Cells During Chemotherapy | CDK6, CCNC, MCL1 | PARP1 366/4885MAP4K1 207/4885MCL1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.